CDK4/6 Inhibitor Dose Adjustments: Clinical Scenarios and Impact on Outcomes

In CDK4/6 Inhibitor Dose Adjustments: Clinical Scenarios and Impact on Outcomes, our experts delve into the following critical questions:

What are the clinical scenarios in which a dose change of a CDK4/6 inhibitor is warranted?

How do dose changes impact outcomes?

Led by the Rose DiMarco, PharmD, Jordan Hill, PharmD, discusses dose modifications of CDK4/6 inhibitors, which are typically warranted in response to adverse events such as grade 3–4 neutropenia, severe diarrhea, hepatotoxicity, or other clinically significant toxicities. Dose changes may also be considered for patients with renal or hepatic impairment, or when drug interactions increase the risk of toxicity. The goal of adjusting the dose is to manage side effects while maintaining therapeutic efficacy and patient quality of life. Clinical trials have demonstrated that reducing the dose of agents like palbociclib, ribociclib, or abemaciclib does not significantly compromise progression-free survival. Pharmacists play a key role in identifying when dose adjustments are needed and coordinating with providers to implement changes safely. By carefully managing dose modifications, clinicians can optimize both the safety and effectiveness of CDK4/6 inhibitor therapy in patients with metastatic breast cancer.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, Optimizing Multidisciplinary Care for Patients on CDK4/6 Inhibitors, further explores strategies for enhancing multidisciplinary collaboration in the management of patients receiving CDK4/6 inhibitors, emphasizing the roles of oncologists, pharmacists, nurses, and other care team members. Faculty discuss practical approaches to improve communication, monitoring, and supportive care to ensure safe, effective, and patient-centered therapy.